However, these molecular changes are able to identify only a portion of cancer patients defined as "non-responders" to EGFR-targeted agents. A number of molecular abnormalities in cancer cells may partly contribute to resistance to anti-EGFR agents (2, 3) . Our group and others have shown that epithelial-to-mesencymal transition (EMT) is a critical event in the metastatic swicth and is generally associated with resistance to molecularly targeted agents in NSCLC models (4, 5) . EMT is a process characterized by loss of polarity and dramatic remodeling of cell cytoskeleton through loss of epithelial cell junction proteins, such as E-cadherin, and gain of mesenchymal markers, such as vimentin (6) . The clinical relevance of EMT and drug insensitivity comes from studies showing an association between epithelial markers and sensitivity to erlotinib in NSCLC cell lines, suggesting that EMT-type cells are resistant to erlotinib (7) . In particular, recent data suggest that cancer cells with EMT phenotype demonstrate stem-cell-like features and strategies reverting EMT could enhance the therapeutic efficacy of EGFR inhibitors (4, 5) .
The Hedgehog (Hh) signaling cascade has emerged as an important mediator of cancer development and metastatic progression. The Hh signaling pathway is comprised of the ligands sonic, indian and desert hedghog (Shh, Ihh, Dhh, respectively), and the cell surface molecules Patched (PTCH) and Gefitinib, Erlotinib, LDE-225 (NVP-LDE225, Erimodegib), Vismodegib (GDC-0449), PHA665752 and cisplatin were purchased from Selleck Chemicals (Selleckchem, Houston, TX, USA).
Cell proliferation assays
Cell proliferation was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously described (4, 18) .
Protein expression analysis
We used the following primary antibodies from Cell Signaling (Beverly, MA): anti-EGFR, antiphospho-EGFR (Tyr1068), anti-p44/42MAPK, anti-phospho-p44/42MAPK, anti-AKT, anti-phospho-AKT (Ser 473), anti-phospho-S6ribosomal protein (Ser235), anti-p70RSK, anti-phospho-p70RSK (Thr389), anti-Vimentin, anti-SLUG, anti-E-Cadherin, anti-Shh, anti-GLI1, anti-GLI2, anti-GLI3, anti-SMO, anti-PTCH, anti-MET, anti-phospho MET (Tyr1234/1235), anti-PARP, anti-HER3, anti-SUFU, anti-NF-κBp65/RELA, anti-phospho-NF-κBp65(Ser536)/phospo-RELA, anti-AXL, anti-phospho-AXL (Tyr702) and anti β-actin. One mg protein lysates were immunoprecipitated with the required antibodies (anti-SMO, anti-MET, anti-SUFU, anti-GLI1 or healthy preimmune serum (PS) anti-mouse for the negative control); immunocomplexes were recovered with protein G Sepharose (GE Healthcare Life Science, UK) and detected by western blot (19) . Each experiment was performed in triplicate.
For the siRNA transfection, cells in the logarithmic growth phase in 6-well plates (5x10 
Tumor xenografts in nude mice
Four-to 6-week old female balb/c athymic (nuþ/nuþ) mice were purchased from Charles River Laboratories. The research protocol was approved and mice were maintained in accordance with the Institutional Guidelines of the Second University of Naples Animal Care and Use Committee. Mice were acclimatized for 1 week before being injected subcutaneously with 10 9 formula π/6 larger diameter (smaller diameter) 2 . Tumor tissues were collected from the xenografts at the end of treatment period and analyzed by immunohistochemistry and by western blotting.
Immunohistochemical analysis on tumor xenografts
We used the following primary antibodies: from Millipore, Merck: MET monoclonal, clone: 4F8.2, dilution 1:500 (Millipore, Merck), PTCH Protein Patched Homolog 1, PPH1, polyclonal, dilution 1:300 (Millipore, Merck), Vimentin monoclonal, dilution 1:100 (Ventana, Roche). After heat-induced antigen retrieval, slides were processed by Benchmark Autostainer (Ventana, Roche) using the UltraView Polymer Detection kit. Negative controls were obtained by omitting the primary antibody.
Expression level of PTCH was scored on the basis of percentage-positive cells and intensity of the staining by two independent pathologists. Staining intensity were scored as follows: 0=negative, 1=weak, 2=moderate, 3=strong. Positive area percentages were graded as follows: grade 0 (<5%), 1 (6% to 15%), 3 (26% to 50%), 4 (51% to 75%) and 5 (>75%). In case of discrepancy, an independent reader was consulted and consensus was obtained. Positivity was determined using the following formula: IHC score= percentage score x staining intensity score. A score of 10 or more was considered positive.
Statistical analysis
p-values lower or equal to 0.05 were considered as statistically significant. For defining the effect of the combined drug treatments, any potentiation was estimated by multiplying the percentage of cells remaining by each individual agent. The synergistic index was calculated as previously described (19) .
In the following equations, A and B are the effects of each individual agent, and AB is the effect of the combination. Subadditivity was defined as %AB / (%A %B) < 0.9; additivity was defined as %AB / (%A %B) = 0.9-1.0; and supra-additivity was defined as %AB / (%A %B) > 1.0.
Results

Activation of Hedgehog signaling pathway in NSCLC cell lines with resistance to EGFR TKIs.
We established an in vitro model of acquired resistance to the EGFRTKI gefitinib using the EGFR Of interest, while we were working to these experiments, data on SMO gene amplification in EGFR mutated NSCLC patients with acquired resistance to anti-EGFR targeted drugs were reported on rebiopsies performed at progression, revealing SMO amplification in two of sexteen patients (12.5%) (24) . For this reason, we evaluated by FISH SMO gene copy number in HCC827-GR cells, in which Since GLI1 is a transcription factor, we tested the functional significance of increased expression of this gene in the EGFR sensitive and resistant cell lines, using a GLI1-responsive promoter within a luciferase reporter expression vector ( Figure 1D ). Analysis of luciferase acitivity of HCC827-GR cells revealed a 6-to 7-fold increase in GLI-responsive promoter activity as compared with HCC827 cells (P < 0.001), suggesting that transcriptional activity of GLI1 is significantly higher in gefitinib-resistant HCC827-GR cells. Furthermore, depletion of GLI1 protein expression by transfection with a GLI1-specific siRNA expression vector led to approximately 65% decrease in GLI1-driven promoter activity in HCC827-GR (P < 0.01) ( Figure 1D As previously mentioned, HCC827-GR cells acquired expression of vimentin and SLUG and loss of Ecadherin when compared to gefitinib-sensitive HCC827 cancer cells along with an increased ability to invade, migrate and to form colonies in semisolid medium (Figure 2A ,B,C). We next evaluated whether the Hh pathway activation was necessary for gefitinib acquired resistance by genetically or by pharmacologically inhibiting Hh components in the HCC827-GR cell line. Knockdown of GLI1 by a GLI1siRNA approach had a very little effect on HCC827-GR cells. However, when gefitinib treatment (1μM) was performed in HCC827-GR cells after GLI1 blockade, invasion, migration and colony forming capabilities were significantly inhibited (Figure 2A ,B,C). Next, we evaluated the effects of two small molecule inhibitors of SMO, such as LDE225 and vismodegib. Treatment with LDE225 (1μM) (Fig 2A,B ,C,D) or with vismodegib (1μM) (data not shown) alone did not significantly affect the viability and the invasion and migration abilities of HCC827-GR cells. Combined treatment with gefitinib and LDE225 (1μM) or vismodegib (1μM) caused inhibition of these parameters in HCC827-GR cells (Figure 2A ,B,C).
Taken together, these data show that Hh activation is required for acquisition of gefitinib resistance in HCC827-GR cells.
As overexpression and activation of MET was found in HCC827-GR cells, we evaluated whether Figure 3A) , revealing an interaction between SMO and MET receptors. To address this issue, we hypothesized a direct interplay between both receptors. SMO immunoprecipitates from HCC827-GR cells showed greater MET binding compared with that from the parental HCC827 cells ( Figure 3B) . As MET has been demonstrated to interact with HER3 to mediate resistance to EGFR inhibitors (25) To study if the cooperation between these two pathways appears also at a downstream level, and considering that, as shown in Figure 3A , MET inhibition partially reduces the levels of GLI1 and PTCH proteins, we analysed luciferase expression of GLI1 reporter vector in HCC827-GR cells after treatment with LDE225, PHA-665752 or both. As shown in Figure 3C , transcriptional activity of GLI1 resulted strongly decreased by the combined treatment. In particular, treatment with single agent LDE225 did not abrogate the trascriptionl activity of GLI1 suggesting a GLI1 non-canonical activation.
In addition, single agent PHA-665752 reduced GLI1-dependent signal, suggesting a role for MET in GLI1 regulation. To better investigate these findings, we hypothesized that MET can regulate GLI1 activity through its nuclear traslocation. We, therefore, analyzed the binding ability of SUFU, a known cytoplasmic negative regulator of GLI1, following treatment of HCC827-GR cells with LDE225 and/or PHA-665752. Indeed, interaction between SUFU and GLI1 was markedly decreased in HCC827-GR cells as compared to HCC827 cells ( Figure 3D ), which further confirmed the role of the activation of 
Hh pathway in this gefitnib-resistant NSCLC model. Furthermore, while combined treatment with LDE225 and PHA-665752 strongly increased the binding between GLI1 and SUFU, suggesting an inhibitory effect on GLI1 activity, also treatment with the MET inhibitor PHA-665752 alone favored the interaction of GLI1 with SUFU ( Figure 3D) , indicating a role of MET on the activation of GLI1.
This phenomenon could be a consequence of the decreased interplay between SMO and MET receptors or the effect of a direct regulation of GLI1 by MET.
Effects of the combined treatment with LDE225 and gefitinib or PHA-665752 on HCC827-GR tumor xenografts
We finally investigated the in vivo antitumor activity of Hh inhibition by LDE225, alone and in combination with gefitinib or with the MET inhibitor in nude mice bearing HCC827-GR cells.
Treatment with gefitinib, as single agent, did not cause any change in tumor size as compared to control untreated mice, confirming that the in vitro model of gefitinib-resistance is valid also in vivo.
Treatment with LDE225 or with PHA-665752 as single agents caused a decrease in tumor size even stronger than that observed in vitro, suggesting a major role of these drugs on tumor microenviroment. However, combined treatments, such as LDE225 plus gefitinib or LDE225 plus PHA-665752, significantly suppressed HCC827-GR tumor growth with a major activity of LDE225 plus PHA-665752 combination. Indeed at 21 days from the starting of treatment, the mean tumor volumes in mice bearing HCC827-GR tumor xenografts and treated with LDE225 plus gefitinib or with LDE225 plus PHA-665752 were 24% and 2%, respectively, as compared to control untreated mice ( Figure 4A ). this particular localization has been described as a marker of poor outcome and tendency to a mesenchymal phenotype (26) . Although the combination of LDE225 and gefitinib resulted in a significant reduction of tumor growth with a concomitant reduction in staining intensity of vimentin, the combination of LDE225 and PHA-665752 was the most effective treatment, with 8/8 (100%) mice having a complete response in their tumors. In fact, histological evaluations of these tumors found only fibrosis and no viable cancer cells. According to western blot analysis of protein extracts harvested from the HCC827-GR xenograft tumors, the levels of phospho-EGFR, phospho-MET and GLI1 resulted decreased after treatment with the respective inhibitor. Interestingly, the combined treatment with LDE225 and PHA-665752 resulted in a stronger inhibition of phospho-MAPK and phopsho-AKT (Supplemental Figure 1) .
Role of Hedgehog pathway in mediating resistance to EGFR-inhibitors in EGFR wild-type nonsmall cell lung cancer.
As shown in Figure 1B analysis that showed a 8-to 9-fold increase in GLI1-dependent promoter activity in these lines as compared with EGFR-inhibitor sensitive H322 and Calu-3 cells, suggesting that trascriptional activity of GLI1 is higher in EGFR TKI-resistant EGFR wild-type NSCLC lines (Supplemental Figure 2A) .
Similarly to HCC827-GR cells, these cells showed also activation of MET. However, as reported in previuos studies (4), MET inhibition alone or in combination with EGFR inhibition or with SMO inhibition resulted ineffective in inhibiting cancer cell proliferation and survival (data not shown).
We therefore tested the effects of Hh inhibition, by silencing GLI1 or by using LDE225, alone and/or in combination with erlotinib. Although knockdown of GLI1 or treatment with LDE225 (1 μM) did not significantly affect NSCLC cell viability, combined treatment with erlotinib restored sensitivity to erlotinib (Supplemental Figure 2B ). We next evaluated the effects of LDE225 alone and/or in combination with erlotinib on the activation of downstream pathways. Erlotinib treatment resulted unable to decrease the phosphorylation levels of AKT and MAPK in H1299 and Calu-3 ER cells ( Figure 5A ). However, when LDE225 was combined with erlotinib, a strong inhibition of AKT and MAPK activation was observed in these EGFR inhibitorresistant cells ( Figure 5A ). Furthermore, flow cytometric analysis revealed that combined treatment with both erlotinib and LDE225 significantly enhanced the apoptotic cell percentage to 65% and 70% (P < 0.001) in H1299 and Calu-3 ER cells, respectivey ( Figure 5B ) confirmed by the induction of PARP cleavage after the combined treatment ( Figure 5A ). These findings suggest that Hh pathway Figure 1F) .
Hedgehog pathway inhibition sensitizes EGFR WT NSCLC cell lines to standard chemotherapy
To extend our preclinical observations, we further investigated the effects of Hh pathway inhibition on sensitivity of EGFR WT NSCLC cells to standard chemotherapy used in this setting and mostly represented by cisplatin.
To investigate the role of Hh pathway in mediating resistance also to chemotherapy we evaluated the 
Resistance to currently available anti-cancer drugs represents a major clinical challenge for the treatment of advanced NSCLC patients. Our previous works (4, 18) reported that, whereas EGFRTKIssensitive NSCLC cell lines express the well-established epithelial markers, cancer cell lines with intrinsic or acquired resistance to anti-EGFR drugs express mesenchymal characteristics, including the expression of vimentin and a fibroblastic scattered morphology. This transition plays a critical role in tumor invasion, metastatic dissemination and the acquisition of resistance to therapies such as EGFRinhibitors. Among the various molecular pathways, the Hh signaling cascade has emerged as an important mediator of cancer development and progression (8) . The Hh signaling pathway is active in human embryogenesis and tissue repair, in cancer stem cell renewal and survival and is critical for lung development. Its aberrant re-activation has been implicated in cellular response to injury and cancer growth (9-11). Indeed, increased Hh signaling has been demonstrated by cigarette smoke extraction exposure in bronchial epithelial cells (12) . In particular, the activation of this pathway correlated with the ability to growth in soft agar and in mice as xenograft, and treatment with Hh inhibitors showed regression of tumors at this stage (12) . Overexpression of Hh-signaling molecules has been demonstrated in NSCLC compared to adjacent normal lung parenchyma, suggesting an involvement in the pathogenesis of this tumor (13, 14) .
Recently, alterations of SMO gene (mutation, amplification, mRNA overexpression) were found in 12.2% of tumors of The Cancer Genome Atlas (TCGA) lung adenocarcinomas by whole exome sequencing (27) . The incidence of SMO mutations was 2.6% and SMO gene amplifications were found in 5% of cases. SMO mutations and amplification strongly correlated with sonic hedgehog gene dysregulation (p<0.0001). In a small case report series, three NSCLC patients with Hh pathway activation had been treated with the SMO inhibitor LDE225 with a significant reduction in tumor burden, suggesting that Hh pathway alterations occur in NSCLC and could be an actionable and valuable therapeutic target (27) . Recently, up-regulation of Shh, both at the mRNA and at the protein 
levels, was demonstrated in the A549 NSCLC cell line, concomitantly with the acquisition of a TGF-β1-induced EMT phenotype (17, 28, 29) and mediated increased cell motility, invasion, and tumor cell aggressiveness (30, 31) .
In the present study, SMO gene amplification has been identified for the first time as a novel mechanism of acquired resistance to EGFR-TKI in EGFR-mutant HCC827-GR NSCLC cells. These In EGFR wild-type NSCLC models, the role of MET amplification/activation is less clear, and in our experience its inhibition did not increased the antitumor activity of SMO inhibitors.
In addition, Hh inhibition contributed to increase the response to cisplatin treatment which is the standard chemotherapic option used in EGFR-WT NSCLC patients and in EGFR-mutated patients after progression on first line EGFR-TKI thus representing a valid contribute to achieve a better disease Collectively the results of the present study provide experimental evidence that activation of Hh pathway, through SMO amplification, is a potential novel mechanism of acquired resistance in EGFRmutated NSCLC patients which occurs concomitantly with MET activation, and the combined inhibition of these two pathways exert a significant antitumor activity. In light of these results, screening of SMO alteration is strongly recommended in EGFR-mutated NSCLC patients with acquired resistance to EGFR TKIs at first progression.
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